Mahesh Allam, MD
Internal Medicine · Lake Wales, FLNPI 1124188180
Payments from drug & device makers
Across 120 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$565
- AstraZeneca$472
- Boehringer Ingelheim$274
- Novo Nordisk$190
- AbbVie$116
- Pfizer$105
- plus $576 from 15 others
What the payments were for
- Food & beverage$2,27999%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 33 | $565 |
| AstraZeneca | 27 | $472 |
| Boehringer Ingelheim | 15 | $274 |
| Novo Nordisk | 6 | $190 |
| AbbVie(2 entities) | 6 | $116 |
| Pfizer | 5 | $105 |
| Abbott | 4 | $93 |
| United Therapeutics Corporation | 3 | $85 |
| Lilly USA, LLC | 5 | $73 |
| Mallinckrodt Hospital Products Inc. | 2 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| Amgen | 2 | $35 |
| Mylan Specialty L.p. | 2 | $35 |
| Insmed, Inc. | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| Insulet Corporation | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
How this compares
$2,299 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 209 | $240,293 |
| OfevNintedanib Esylate | 17 | $223,799 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 225 | $222,875 |
| EliquisApixaban | 198 | $219,286 |
| FarxigaDapagliflozin Propanediol | 218 | $182,578 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 30 | $115,397 |
| JanuviaSitagliptin Phosphate | 88 | $111,581 |
| OzempicSemaglutide | 87 | $92,388 |
| MounjaroTirzepatide | 66 | $86,204 |
| TrulicityDulaglutide | 59 | $69,574 |
| XareltoRivaroxaban | 47 | $57,615 |
| EntrestoSacubitril/Valsartan | 46 | $55,602 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $44,085 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $36,816 |
| SymbicortBudesonide/Formoterol Fumarate | 79 | $30,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Ofev, Stiolto Respimat, Spiriva Respimat, Tradjenta | $274 | $541,339311 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $565 | $254,430269 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $472 | $226,828310 claims |
| PfizerEliquis | $105 | $219,286198 claims |
| Lilly USA, LLCMounjaro, Trulicity | $73 | $155,778125 claims |
| Novo NordiskOzempic, Rybelsus | $190 | $122,409105 claims |
| Johnson & JohnsonXarelto, Prezcobix, Invokana | $14 | $106,12380 claims |
| NovartisEntresto | $23 | $55,60246 claims |
| AbbVieCreon, Vraylar | $116 | $50,41438 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $29,43942 claims |
| Sanofi-aventis U.S. LLCLantus | $15 | $13,53335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Lake Wales
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.